Search Results - "Vierling, J M"

Waitlist Mortality Decreases with Increased Use of Extended Criteria Donor Liver Grafts at Adult Liver Transplant Centers by Barshes, N. R., Horwitz, I. B., Franzini, L., Vierling, J. M., Goss, J. A.

“…Extended criteria donor (ECD) liver allografts are often allocated to less severely ill liver transplant (LT) candidates who are at a relatively lower risk of…”
Get full text

Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy by Landis, C. S., Ghabril, M., Rustgi, V., Di Bisceglie, A. M., Maliakkal, B., Rockey, D. C., Vierling, J. M., Bajaj, J., Rowell, R., Santoro, M., Enriquez, A., Jurek, M., Mokhtarani, M., Coakley, D. F., Scharschmidt, B. F.

“…Background Overt hepatic encephalopathy (OHE) is a frequent complication of decompensated cirrhosis. Aims A multicenter prospective observational study was…”
Get full text

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis by Ghany, Marc G., Ayola, Brick, Villamil, Federico G., Gish, Robert G., Rojter, Sergio, Vierling, John M., Lok, Anna S.

“…Long‐term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. The aim of…”
Get full text

Expert clinical management of autoimmune hepatitis in the real world by Liberal, R., Boer, Y. S., Andrade, R. J., Bouma, G., Dalekos, G. N., Floreani, A., Gleeson, D., Hirschfield, G. M., Invernizzi, P., Lenzi, M., Lohse, A. W., Macedo, G., Milkiewicz, P., Terziroli, B., Hoek, B., Vierling, J. M., Heneghan, M. A., Pares, A., Montano‐Loza, A. J., Granito, A., Kremer, A. E., Floreani, A., Lohse, A. W., Hoek, B., Terziroli, B., Schramm, C., Lammert, C., Cancado, E. L. R., Bjornsson, E., Lammert, F., Dalekos, G. N., Bouma, G., Hirschflield, G. M., Macedo, G., Hofer, H., Mackay, I., Neuberger, J., Vierling, J. M., Drenth, J.P.H., Nieuwkerk, C.M.J., Muratori, L., Lenzi, M., Swain, M., Heneghan, M., Zeniya, M., Chazouilleres, O., Gines, P., Invernizzi, P., Milkiewicz, P., Andrade, R. J., Chapman, R., Berg, T., Buuren, H., Ma, X.

“…Summary Background High‐quality data on the management of autoimmune hepatitis (AIH) are scarce. Despite published guidelines, management of AIH is still…”
Get full text

Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection by Hu, K Q, Vierling, J M, Redeker, A G

“…The estimated prevalence of hepatitis C virus infection in the US is approximately 1.8%. Although interferon monotherapy and combination therapy of interferon…”
Get full text

Sirolimus‐induced hyperlipidaemia in liver transplant recipients is not dose‐dependent by Firpi, R. J., Tran, T. T., Flores, P., Nissen, N., Colquhoun, S., Shackleton, C., Martin, P., Vierling, J. M., Poordad, F. F.

“…Summary Background : Sirolimus is a potent immunosuppressive medication that acts by inhibiting T‐cell proliferation. It has been used in kidney…”
Get full text

Acute hepatitis associated with the Chinese herbal product Jin Bu Huan by WOOLF, G. M, PETROVIC, L. M, VIERLING, J. M, ROJTER, S. E, WAINWRIGHT, S, VILLAMIL, F. G, KATKOV, W. N, MICHIELETTI, P, WANLESS, I. R, STERMITZ, F. R, BECK, J. J

“…To describe the hepatotoxicity associated with ingestion of the Chinese herbal product Jin Bu Huan Anodyne Tablets (Lycopodium, serratum) and to propose…”
Get full text

Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis by Fernandes, Neville F, Redeker, Allan G, Vierling, John M, Villamil, Federico G, Fong, Tse-Ling

“…Autoimmune hepatitis is a form of chronic liver disease characterized by progressive hepatocellular inflammation, which usually responds to treatment with…”
Get full text

Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial by Lagging, M., Brown, A., Mantry, P. S., Ramji, A., Weilert, F., Vierling, J. M., Howe, A., Gendrano III, I. N., Hwang, P., Zhang, B., Wahl, J., Robertson, M., Mobashery, N.

“…Summary Grazoprevir (MK‐5172, Merck & Co., Inc.) is a selective inhibitor of the hepatitis C virus (HCV) NS3/4a protease. The aim of this study was to evaluate…”
Get full text

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio by Mokhtarani, M., Diaz, G.A., Rhead, W., Berry, S.A., Lichter-Konecki, U., Feigenbaum, A., Schulze, A., Longo, N., Bartley, J., Berquist, W., Gallagher, R., Smith, W., McCandless, S.E., Harding, C., Rockey, D.C., Vierling, J.M., Mantry, P., Ghabril, M., Brown, R.S., Dickinson, K., Moors, T., Norris, C., Coakley, D., Milikien, D.A., Nagamani, S.C., LeMons, C., Lee, B., Scharschmidt, B.F.

“…Phenylacetic acid (PAA) is the active moiety in sodium phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB, HPN-100). Both are approved for treatment of…”
Get full text

Introduction to hepatitis B transplantation by Vierling, J M, Teperman, L W

Get more information

Immunology of acute and chronic hepatic allograft rejection by Vierling, J M

Get more information

Trans-Activation of HLA-DR Gene by Hepatitis B Virus X Gene Product by Hu, Ke-Qin, Vierling, John M., Siddiqui, Aleem

“…Hepatocellular injury during hepatitis B virus (HBV) infection has been postulated to result from a human leukocyte antigen (HLA)-restricted T-lymphocyte host…”
Get full text

Immortalized intrahepatic mouse biliary epithelial cells: Immunologic characterization and immunogenicity by Hreha, Gabriella, Jefferson, Douglas M., Yu, Chang‐Hong, Grubman, Shelley A., Alsabeh, Randa, Geller, Stephen A., Vierling, John M.

“…Nonsuppurative destructive cholangitis (NSDC), a process of T‐cell–mediated destruction of biliary epithelia observed in primary biliary cirrhosis (PBC),…”
Get full text

Up-Regulation of Intercellular Adhesion Molecule 1 Transcription by Hepatitis B Virus X Protein by Hu, Ke-Qin, Yu, Chang-Hong, Vierling, John M.

“…Intercellular adhesion molecule 1 (ICAM-1), a counter-receptor for lymphocyte function-associated antigen 1 on T cells, is critically important to a wide…”
Get full text

Immune disorders of the liver and bile duct by Vierling, J M

“…Several hepatobiliary diseases appear to be mediated by the host immune response. They can be subdivided into those in which the immune reaction is against an…”
Get more information

Molecular diagnostic techniques for viral hepatitis by Hu, K Q, Vierling, J M

“…The five different viruses that cause human viral hepatitis, A, B, C, D, and E share the unique property of hepatotropism. Identification of the nucleic acid…”
Get more information

Treatment of acetaminophen-induced fulminant hepatic failure with a bioartificial liver by Watanabe, F.D., Shackleton, C.R., Cohen, S.M., Goldman, D.E., Arnaout, W.S., Hewitt, W., Colquhoun, S.D., Fong, T.-L., Vierling, J.M., Busuttil, R.W., Demetriou, A.A.

Get full text

Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts by Vierling, J M, Fennell, Jr, R H

“…Cholestasis and injury of interlobular bile ducts occur during rejection of human hepatic allografts. However, knowledge of the nature and progression of bile…”
Get more information

Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure by Villamil, F G, Hu, K Q, Yu, C H, Lee, C H, Rojter, S E, Podesta, L G, Makowka, L, Geller, S A, Vierling, J M

“…The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported…”
Get more information